Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study

Final Data from VAX-24 Infant Phase 2 Dose-Finding Study Consistent with Previously Reported Positive Interim Data; Provide Additional Evidence Supporting Higher VAX-31 Doses Being Evaluated in Ongoing Infant Phase 2 Study Modified VAX-31 Infant Phase 2 Dose-Finding Study Advanced to Third and Final Stage Company Expects to Initiate VAX-31 Adult Pivotal, Non-Inferiority Study in December 2025 with Topline Data in 2026 Company Establishing Fill-Finish Manufacturing in North Carolina as Key Element of Long-T ...